Kurogochi Kentaro, Takahashi Arane, Nii Yasuyuki, Chen Ayaka, Nishiyama Masako, Furusato Shimon, Sugiya Hiroshi, Uechi Masami
JASMINE Veterinary Cardiovascular Medical Center, Yokohama, Japan.
Department of Clinical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh, North Carolina, USA.
Vet Surg. 2025 Oct;54(7):1366-1377. doi: 10.1111/vsu.14278. Epub 2025 Jun 9.
To compare the utility of a saline-based modified del Nido (mDN) cardioplegia solution with a conventional institutional technique (multidose St. Thomas blood cardioplegia) for mitral valve repair (MVR) in dogs.
Prospective, randomized, open-label trial.
Forty client-owned dogs with myxomatous mitral valve disease (stage B2 and C) eligible for MVR were divided into control and modified mDN groups.
Cardioplegia was induced in the control group using 50% blood containing St. Thomas solution every 10 min. In the mDN group, a cardioplegia solution containing 20% blood was administered once or when required. As the primary outcome, serum cardiac troponin I levels were compared 12 h postoperatively between the groups. The other clinical findings were evaluated as secondary outcomes.
Troponin levels 12 h after surgery were a median of 27.8 ng/mL (interquartile range, 15.1-43.2) in the control group and 19.4 ng/mL (15.2-33.6) in the mDN group (p = .478). The sinus rhythm recovery time following aortic cross-clamp removal was 362 s (103-995) in the control group and 60 s (44-605) in the mDN group (p = .027). The total amount of crystalloid cardioplegia solution required was 12.6 mL/kg (11.3-15.0) in the control group and 23.6 mL/kg (18.0-35.1) in the mDN group (p < .001).
Cardiac troponin I levels did not show differences between the groups. The saline-based mDN cardioplegia facilitated earlier sinus rhythm recovery.
Saline-based mDN cardioplegia may be a viable alternative for canine MVR.
比较基于生理盐水的改良del Nido(mDN)心脏停搏液与传统机构技术(多剂量圣托马斯血液心脏停搏液)在犬二尖瓣修复(MVR)中的效用。
前瞻性、随机、开放标签试验。
40只患有黏液瘤性二尖瓣疾病(B2和C期)且适合进行MVR的客户拥有的犬被分为对照组和改良mDN组。
对照组每10分钟使用含50%血液的圣托马斯溶液诱导心脏停搏。在mDN组,给予含20%血液的心脏停搏液一次或根据需要给予。作为主要结局,比较两组术后12小时的血清心肌肌钙蛋白I水平。其他临床发现作为次要结局进行评估。
术后12小时,对照组肌钙蛋白水平中位数为27.8 ng/mL(四分位间距,15.1 - 43.2),mDN组为19.4 ng/mL(15.2 - 33.6)(p = 0.478)。主动脉阻断解除后窦性心律恢复时间,对照组为362秒(103 - 995),mDN组为60秒(44 - 605)(p = 0.027)。对照组所需晶体心脏停搏液总量为12.6 mL/kg(11.3 - 15.0),mDN组为23.6 mL/kg(18.0 - 35.1)(p < 0.001)。
两组间心肌肌钙蛋白I水平无差异。基于生理盐水的mDN心脏停搏液有助于更早恢复窦性心律。
基于生理盐水的mDN心脏停搏液可能是犬MVR的一种可行替代方案。